מחקר חדש

NEW YORK (Reuters Health) - A newer, longer-acting form of Byetta (exenatide) that is given once weekly actually achieves better blood sugar control in diabetics than does the standard formulation, which is given twice daily, according to a report in The Lancet. In a new study, Dr. Daniel J. Drucker, from Mount Sinai Hospital in Toronto, AND colleagues compared the two formulations, both of which are injectable drugs, in 265 patients with type 2 diabetes. The doses of the long-acting AND standard formulations of Byetta were 2 milligrams once a week AND 10 micrograms twice a day, respectively. At 30-week follow-up, patients treated with the long-acting formulation showed significantly better blood sugar control than did those given the standard formulation. Moreover, 77 percent of patients given the long-acting formulation achieved their goal sugar levels compared with 61 percent of subjects who received the older formulation. These benefits were achieved without increasing the risk of excessively low blood sugar levels OR compromising weight loss. The results suggest that the newer, long-acting Byetta formulation "offers a promising treatment option for the management of type 2 diabetes," Drucker AND colleagues conclude. "When the once-a-week (Byetta) formulation becomes available, after confirmation AND extension of today's positive results, this new strategy might substantially change the management of type 2 diabetes," Dr. Andre J. Scheen, from the University of Liege in Belgium, comments in a related editorial. SOURCE: The Lancet, September 8th online 2008. Copyright © 2006 Reuters Limited. All rights reserved. Republication OR redistribution of Reuters content, including by framing OR similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors OR delays in the content, OR for any actions taken in reliance thereon. Reuters AND the Reuters sphere logo are registered trademarks AND trademarks of the Reuters group of companies around the world. [img]http://smily.hit.bg/comfort.gif[/img][img]http://smily.hit.bg/comfort.gif[/img]

http://articles.mercola.com/sites/articles/archive/2008/09/13/diabetes-drug-causing-deaths.aspx?source=nl ואולי כדאי לקרא גם את האינפורמציה הזו: The U.S. Food AND Drug Administration (FDA) plans to strengthen warnings about life-threatening pancreas problems linked to the type 2 diabetes drug Byetta, after receiving two reports of deaths AND four other hospitalizations in Byetta users. All six patients had hemorrhagic pancreatitis (inflammation of the pancreas with bleeding) OR necrotizing pancreatitis (in which the inflamed pancreas destroys itself). The four survivors were still recovering at the time that the FDA learned of their illness. Byetta, given by injection, was approved by the FDA in 2005. Last October, the FDA noted 30 reports of acute pancreatitis (sudden inflammation of the pancreas) in Byetta users. Sources: WebMD August 18, 2008 וד"ר מרקולה מוסיף: Byetta was originally approved as an “add-on” drug for diabetes, meaning that it’s usually prescribed along with other drugs like metformin AND insulin. Even as an add-on drug, which are widely known as being less profitable for the drug companies, it brings in about $197 million a quarter, according to Eli Lilly. Perhaps this has something to do with its high price tag. According to BNET, it costs up to $225 a month, AND is up to 10 times more expensive than generics. Meanwhile, the side effects, as the above report reveals, are steep. The most common side effects, according to the drug’s patient information, are nausea, vomiting, diarrhea, dizziness, headache, feeling jittery AND stomach acid. Byetta can also cause abdominal pain, AND possibly life-threatening pancreatitis. Pancreattis is usually marked by abdominal pain, nausea, vomiting AND fever, AND it can lead to potentially fatal complications including: • Infection • Respiratory failure • Shock (extremely low blood pressure that can cause death within minutes) • Pseudocysts AND abscess, which may require surgery to treat If pancreatitis becomes chronic, it can actually trigger several diseases, one of which is diabetes! Already, two Byetta users have died from pancreatitis, AND at least 30 other reports have surfaced. One of these victims, a man from Virginia, is suing the manufacturer AND marketers of the drug, Amylin Pharmaceuticals AND Eli Lilly, due to his injuries. According to his lawsuit, Amylin "failed to adequately warn prescribing physicians of the risk of pancreatitis, of measures needed to properly assess the appropriateness of prescribing the drug to certain categories of patients, AND of measures doctors AND patients could AND should take to minimize the risk." It seems a storm is slowly brewing over yet another diabetes drug, which is not surprising considering their sordid history. ללינק המלא: http://articles.mercola.com/sites/articles/archive/2008/09/13/diabetes-drug-causing-deaths.aspx?source=nl אז רק בריאות ג'ודי אליאס

בלי קשר, מרקולה ידוע בתור חנטריש, אפילו הועמד למשפט. מי שמוכר כל מינ י תוספים ומפרסם אותם אינו אמין בעיני. י

שלום לכולם, אסיר תודה אהיה לכם אם לא תפיצו כל מיני מאמרי מחקר במפורט כאלו שיש בהם להראות כאילו על "פתרונות" תרופתיים או אחרים, "שיש בהם" כדי לשפר או לשנות את הטיפולים המקובלים. המחקרים רבים ומגוונים, כל כנס מדעי לסוכרת מביא עשרות שכאלו, והמרחק בין הניסוי בעכברים או בני אדם לכך שהתרופה תכנס לסל התרופות כמשוללת סיבוכים ותופעות לוואי הוא רב ביותר. אני ממליץ אם כן לסכם בשורה או שתיים את מה שאתם רוצים לציין בפני משתתפי האתר, ולהביא את המקור, כך שכל מי שירצה להתעמק יוכל להכנס ישירות לאתר המדובר. כמו כן אשמח אם לא תתנו ציונים מפורשים מסוג "שרלטן" או "חנטריש" , גם אם הם תואמי המציאות, כי קיימים סביבנו כל מיני עורכי דין נשכניים האורבים לכל הזדמנות לאיים ולנסות לסחוט את האתרים והכותבים בהם. אשר לביאטה "ארוכת הטווח" - יש להמתין ולראות אם אין בה סיכון יתר בהשוואה לביאטה קצרת הטווח, לאור ההודעות האחרונות על סיבוכים אפשרים מתרופה זו והשפעתה על הלבלב.